Novo Nordisk A/S (NVO) on Wednesday reported fourth-quarter earnings of $4.04 billion. The Bagsvaerd, Denmark-based company said it had net income of 91 cents per share. The results exceeded Wall ...

Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and ...

On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...

This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members ...

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on ...

Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...

LONDON (Reuters) – The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a ...

At the Annual General Meeting on 27 March 2025, the Board of Directors will propose a final dividend of DKK 7.90 for 2024 per share. The expected total dividend for 2024 will increase 21% to DKK 11.40 ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 – Novo ...

Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission (SEC ...